Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Commentary: IFN-k is a rheostat for development of psoriasiform inflammation
University of Modena & Reggio Emiliana
Modena, Italy
PUBLICATION
IFN-k is a rheostat for development of psoriasiform inflammation. Gharaee-Kermani M, Estadt SN, Tsoi LC, Wolf-Fortune SJ, Liu J, Xing X, Theros J, Reed TJ, Lowe L, Gruszka D, Ward NL, Gudjonsson JE, Kahlenberg JM. J Invest Dermatol. 2022 Jan;142(1):155-165.e3. doi: 10.1016/j.jid.2021.05.029. Epub 2021 Aug 5. PMID: 34364883; PMCID: PMC8688309.
Why this article was chosen
Commentary
As pointed out by Garzorz-Stark and Kilian Eyerich1 in the Commentary related to the present article, in psoriatic skin, there are two immune axes involving IFNs: pDC-derived IFN-a and keratinocytes-derived IFN-k, both leading to type 1 (Th1, IL-12, and IFN-g) and type 3 (IL-23, Th17, IL-17) immune responses. This also implies an active role for keratinocytes in psoriasis.
Categories
Recent Posts
IFPA and IPC Partnership One Year Later — Joining the Clinical and Patient Perspectives
Meet Our Newest Councilors
IPC and IFPA Joint Statement on Diversity and Inclusion
Also Read
Commentary: Association of Apremilast with Vascular Inflammation and Cardiometabolic Function in Patients with Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial
Recently, a study was conducted on the effect of apremilast on vascular inflammation and cardiometabolic functions with an impressively comprehensive set of markers for vascular inflammation and cardiometabolic disease. Peter van de Kerkhof, MD, PhD, provides his expert opinion on the overall conclusion and the implications of this study are discussed.
Commentary: Deucravacitinib Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results from the 52-week, Randomized, Double-blinded, Placebo-controlled Phase 3 POETYK PSO-1 Trial
The United States Food and Drug Administration (FDA) has approved deucravacitinib to treat psoriasis. Recently, 52-week efficacy and safety data of deucravacitinib were compared and contrasted with placebo and apremilast. The outcome of this comparative study lends support for the position of deucravacitinib in the spectrum of treatments for psoriasis.
Commentary: Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis
Real-world evidence studies become crucial to achieving the evidence needed in clinical practice. But how are data evaluated in the complexity of the real world? Alexander Egeberg, MD, PhD, DMSc, discusses a present study that examined drug survival among 16,122 treatment courses of biologic therapy with either guselkumab, ixekizumab, secukinumab, ustekinumab, or adalimumab, using United Kingdom registry data.
Subscribe to the IPC Newsletter